Abstract
Psoriasis is a chronic, inflammatory autoimmune skin disease with a significant genetic component. While genome-wide association studies (GWAS) have identified over 40 susceptibility loci, a substantial portion of the disease's heritability remains unexplained. This study addresses this "missing heritability" by focusing on noncoding genetic variants flanking target genes. Through a massive three-stage sequencing and genotyping approach involving over 32,000 Han Chinese individuals, we confirmed four known susceptibility loci and identified three novel loci: 4q24 (NFKB1), 12p13.3 (near CD27-LAG3), and 17q12 (IKZF3). These findings highlight the critical role of regulatory variants in immune and inflammatory pathways, particularly the NF-κB signaling pathway, in the pathogenesis of psoriasis.
Introduction
Psoriasis is characterized by immune-mediated skin inflammation. Despite the success of GWAS in identifying dozens of risk loci, these common variants do not fully account for the genetic risk. Most GWAS-identified variants reside in noncoding regions, suggesting that regulatory elements—which control gene expression rather than protein structure—are key to understanding the disease. This study aimed to identify novel susceptibility loci by performing an in-depth analysis of noncoding variants flanking candidate genes.
Methods
The researchers implemented a robust three-stage design:
- Exome Sequencing (Discovery): Exomes and their immediate flanking noncoding regions (~200 bp) were sequenced in an initial cohort.
- Targeted Sequencing (Extension): Deep sequencing of 1,362 candidate immune-related genes was performed in a larger cohort.
- Genotyping (Validation): The top 22 suggestive variants were genotyped in a third independent cohort using MALDI-TOF mass spectrometry.
Statistical associations were evaluated using logistic regression under an additive model, and linkage disequilibrium (LD) analysis was used to confirm the independence of genetic signals.
Datasets
The study utilized three distinct cohorts of Han Chinese individuals, totaling 15,207 cases and 17,103 healthy controls:
- Stage 1 (Exome): 781 cases and 676 controls.
- Stage 2 (Targeted): 9,946 cases and 9,906 controls.
- Stage 3 (Genotyping): 4,480 cases and 6,521 controls.
Key Results
The combined analysis of the three stages successfully replicated several known loci and identified three novel susceptibility regions reaching genome-wide significance ($P < 5 \times 10^{-8}$).
Confirmed and Novel Loci (Stage I & II)
The study confirmed the association of IL12B, IFIH1, and ERAP1. Notably, it identified the 4q24 locus (NFKB1) as a novel susceptibility region.
Additional Novel and Suggestive Loci
Two additional novel loci were identified at 12p13.3 and 17q12. The study also found suggestive evidence for loci at 3p21.31 and 17q25.
Summary of novel findings:
- 4q24 (NFKB1): rs1020760 ($P = 2.19 \times 10^{-8}$, OR = 1.12).
- 12p13.3 (near CD27-LAG3): rs758739 ($P = 4.08 \times 10^{-8}$, OR = 0.91).
- 17q12 (IKZF3): rs10852936 ($P = 1.96 \times 10^{-8}$, OR = 1.10).
Discussion and Limitations
The discovery of a variant in NFKB1 provides a direct genetic link to a master regulator of inflammation. NF-κB controls the production of pro-inflammatory cytokines like TNF-α and IL-6, which are central to psoriasis pathology. Furthermore, the identification of loci containing IKZF3, CD27, and LAG3—genes involved in T-cell and B-cell immunity—suggests a shared genetic architecture with other autoimmune diseases like lupus and multiple sclerosis.
A primary limitation is that no functional coding variants were found within these new loci, implying the causal mechanisms are regulatory (e.g., altering transcription factor binding). Future functional studies are required to pinpoint the exact causal genes and molecular pathways involved.
Summary updated